Close Menu

NEW YORK (360Dx) – Metabolic dysregulation has emerged as a major focus for research into autism spectrum disorder (ASD) with a number of academic groups and commercial outfits looking to such abnormalities to diagnose and treat the condition.

Last year, Madison, Wisconsin-based Stemina Biomarker Discovery launched its first metabolomic test for diagnosing ASD through its NeuropointDx division.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.